新型口服抗凝药物：现在就应开始讨论监测和依从性问题！
New oral anticoagulants: discussion on monitoring and adherence should start now!
机构信息
Department of Internal Medicine, Laboratory for Clinical Haemostasis and Thrombosis, Maastricht University Medical Center, PO Box 616, Maastricht, MD, 6200, the Netherlands.
出版信息
Thromb J. 2013 Jun 28;11(1):8. doi: 10.1186/1477-9560-11-8.
Abstract
New oral anticoagulants (NOACs) have been introduced to improve anticoagulant therapy worldwide, but safe implementation may require additional measures. First, optimization of dose adjustment based on therapeutic levels of the drug may be more appropriate than fixed dose therapy. The development and implementation in quantitative laboratory assays will enable further dose optimization. Second, non-adherence to medication is a potential threat to the safe use of NOACs. Since cardiovascular medication may not be optimally used in about 50% of patients, procedures to improve adherence are imperative, also for NOAC therapy and in particular in elderly patients.
摘要
新型口服抗凝药物（NOACs）的问世改善了全球的抗凝治疗，但安全实施可能需要额外的措施。首先，基于药物治疗水平进行剂量调整的优化可能比固定剂量治疗更合适。在定量实验室检测中的发展和应用将进一步优化剂量。其次，不遵医嘱是 NOACs 安全使用的潜在威胁。由于心血管药物约有 50%的患者未得到最佳使用，因此提高依从性的措施是必要的，这同样适用于 NOAC 治疗，尤其是老年患者。
相似文献
1
New oral anticoagulants: discussion on monitoring and adherence should start now!新型口服抗凝药物：现在就应开始讨论监测和依从性问题！
Thromb J. 2013 Jun 28;11(1):8. doi: 10.1186/1477-9560-11-8.
2
Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.非维生素 K 拮抗剂口服抗凝剂在房颤患者中应用的实验室监测：综述。
JAMA Cardiol. 2017 May 1;2(5):566-574. doi: 10.1001/jamacardio.2017.0364.
3
Laboratory Monitoring: A Turning Point in the Use of New Oral Anticoagulants.实验室监测：新型口服抗凝剂使用中的一个转折点。
Ther Drug Monit. 2016 Feb;38(1):12-21. doi: 10.1097/FTD.0000000000000247.
4
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.2018 年欧洲心脏病学会实用指南：非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中的应用：执行摘要。
Europace. 2018 Aug 1;20(8):1231-1242. doi: 10.1093/europace/euy054.
5
The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.2018 年欧洲心脏病学会关于非维生素 K 拮抗剂口服抗凝剂在心房颤动患者中应用的实用指南。
Eur Heart J. 2018 Apr 21;39(16):1330-1393. doi: 10.1093/eurheartj/ehy136.
6
Community pharmacy-based study of adherence to non-vitamin K antagonist oral anticoagulants.基于社区药房的非维生素 K 拮抗剂口服抗凝剂依从性研究。
Heart. 2020 Nov;106(22):1740-1746. doi: 10.1136/heartjnl-2020-316781. Epub 2020 Jun 23.
7
Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.新型口服抗凝药（NOACs）的处方量已超过华法林：探究医生如何选择抗凝治疗药物。
Eur J Clin Pharmacol. 2018 Mar;74(3):323-330. doi: 10.1007/s00228-017-2374-4. Epub 2017 Nov 17.
8
Assessment of novel oral anticoagulant use within a community teaching hospital.社区教学医院内新型口服抗凝剂使用情况的评估
Saudi Pharm J. 2017 Jan;25(1):93-98. doi: 10.1016/j.jsps.2016.02.002. Epub 2016 Feb 15.
9
Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.优化新型口服抗凝剂在心房颤动中预防卒中的未解决问题及研究重点。
Thromb Haemost. 2014 May 5;111(5):808-16. doi: 10.1160/TH13-09-0741. Epub 2013 Nov 28.
10
Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence.非维生素K拮抗剂口服抗凝药：关于每日一次与每日两次给药方案的考量及其对药物依从性的潜在影响
Europace. 2015 Apr;17(4):514-23. doi: 10.1093/europace/euu311. Epub 2015 Feb 17.
引用本文的文献
1
A Real-World, Prospective, Observational Study of Rivaroxaban on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-Valvular Atrial Fibrillation: XARENAL.利伐沙班预防韩国非瓣膜性心房颤动肾损害患者卒中及非中枢神经系统栓塞的真实世界、前瞻性观察研究：XARENAL研究
Korean Circ J. 2025 Feb;55(2):121-131. doi: 10.4070/kcj.2024.0154. Epub 2024 Oct 23.
2
The relationship between DOAC levels and clinical outcomes: The measures tell the tale.直接口服抗凝剂（DOAC）水平与临床结局之间的关系：这些指标说明了情况。
J Thromb Haemost. 2020 Dec;18(12):3163-3168. doi: 10.1111/jth.15104. Epub 2020 Oct 19.
3
Methodological considerations for investigating oral anticoagulation persistence in atrial fibrillation.探讨心房颤动患者口服抗凝药物持续性的方法学考虑。
Eur Heart J Cardiovasc Pharmacother. 2021 May 23;7(3):251-260. doi: 10.1093/ehjcvp/pvaa052.
4
Direct oral anticoagulants: a review of common medication errors.直接口服抗凝剂：常见用药错误综述。
J Thromb Thrombolysis. 2019 Jan;47(1):146-154. doi: 10.1007/s11239-018-1752-9.
5
Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study.疾病认知、药物认知、抗凝相关生活质量与国际标准化比值（INR）控制之间的关联：转换研究的见解
Res Pract Thromb Haemost. 2018 Jun 7;2(3):497-507. doi: 10.1002/rth2.12116. eCollection 2018 Jul.
6
Contemporary utilization of antithrombotic therapy for stroke prevention in patients with atrial fibrillation: an audit in an Australian hospital setting.当代心房颤动患者预防卒中的抗血栓治疗应用情况：澳大利亚医院环境下的一项审计
Ther Adv Drug Saf. 2018 Feb;9(2):97-111. doi: 10.1177/2042098617744926. Epub 2017 Dec 13.
7
Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.新型口服抗凝药（NOACs）的处方量已超过华法林：探究医生如何选择抗凝治疗药物。
Eur J Clin Pharmacol. 2018 Mar;74(3):323-330. doi: 10.1007/s00228-017-2374-4. Epub 2017 Nov 17.
8
Once-daily rivaroxaban for long-term stroke prevention in patients with atrial fibrillation.每日一次利伐沙班用于心房颤动患者的长期卒中预防。
Eur Heart J Suppl. 2016 Apr 20;18(Suppl D):D7-D15. doi: 10.1093/eurheartj/suv061.
9
Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.非维生素K拮抗剂口服抗凝剂每日一次给药对心房颤动患者的益处。
Eur Heart J Suppl. 2016 Apr 20;18(Suppl D):D1-D6. doi: 10.1093/eurheartj/suv062. Epub 2016 Apr 21.
10
Using Artificial Intelligence to Reduce the Risk of Nonadherence in Patients on Anticoagulation Therapy.利用人工智能降低抗凝治疗患者的不依从风险。
Stroke. 2017 May;48(5):1416-1419. doi: 10.1161/STROKEAHA.116.016281. Epub 2017 Apr 6.
本文引用的文献
1
Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis.凝血酶和Xa因子口服直接抑制剂的检测：国际血栓与止血学会科学与标准化委员会抗凝控制小组委员会的建议
J Thromb Haemost. 2013 Jan 24. doi: 10.1111/jth.12149.
2
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study.106 例接受大型骨科手术后预防静脉血栓栓塞症的患者中达比加群和利伐沙班的测量：一项观察性研究。
J Thromb Thrombolysis. 2013 Feb;35(2):140-6. doi: 10.1007/s11239-012-0803-x.
3
4
Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.在真实生活条件下，低剂量利伐沙班对患者特定凝血检测和凝血因子活性的体外效应。
Thromb Haemost. 2013 Jan;109(1):127-36. doi: 10.1160/TH12-04-0228. Epub 2012 Nov 8.
5
Do new oral anticoagulants require laboratory monitoring? The clinician point of view.新型口服抗凝药物需要实验室监测吗？临床医生的观点。
Thromb Res. 2012 Oct;130 Suppl 1:S88-9. doi: 10.1016/j.thromres.2012.08.286.
6
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects.阿哌沙班，一种口服、直接的 Xa 因子抑制剂：在健康受试者中的单次剂量安全性、药代动力学、药效学和食物影响。
Br J Clin Pharmacol. 2013 Feb;75(2):476-87. doi: 10.1111/j.1365-2125.2012.04369.x.
7
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.美国食品药品监督管理局决定不批准达比加群110毫克的剂量：给我们一条出路。
Am J Med. 2012 Aug;125(8):732. doi: 10.1016/j.amjmed.2011.10.035. Epub 2012 May 18.
8
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism.利伐沙班口服治疗有症状的肺栓塞。
N Engl J Med. 2012 Apr 5;366(14):1287-97. doi: 10.1056/NEJMoa1113572. Epub 2012 Mar 26.
9
A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.一项评估阿哌沙班与依诺肝素在健康受试者中药代动力学、药效学和安全性相互作用的随机评估。
Thromb Haemost. 2012 May;107(5):916-24. doi: 10.1160/TH11-09-0634. Epub 2012 Mar 8.
10
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.口服抗凝治疗：抗血栓治疗和血栓预防，第 9 版：美国胸科医师学会基于证据的临床实践指南。
Chest. 2012 Feb;141(2 Suppl):e44S-e88S. doi: 10.1378/chest.11-2292.
Zotero 插件